Focused On-demand Library for DDB1- and CUL4-associated factor 12

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q5T6F0

UPID:

DCA12_HUMAN

Alternative names:

Centrosome-related protein TCC52; Testis cancer centrosome-related protein; WD repeat-containing protein 40A

Alternative UPACC:

Q5T6F0; A8KA70; D3DRL6; Q5T6E9; Q5T6F1; Q6P3V0; Q7L4F8; Q96PZ5; Q9NXA9; Q9UFJ1

Background:

DDB1- and CUL4-associated factor 12 (DCAF12) serves as a substrate-recognition component of the DCX E3 ubiquitin-protein ligase complex, pivotal in the DesCEND pathway. It targets proteins with specific C-terminal motifs for ubiquitination and degradation, including those with diglutamate or glutamate-leucine degrons. This process is crucial for cellular functions such as starvation-induced autophagy.

Therapeutic significance:

Understanding the role of DDB1- and CUL4-associated factor 12 could open doors to potential therapeutic strategies.